Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome

Cancer

Volumn 110, Issue 8, 2007, Pages 1832-1839

  Truong, Tony H ^a   Beyene, Joseph ^a   Hitzler, Johann ^a   Abla, Oussama ^a   Maloney, Anne Marie ^a   Weitzman, Sheila ^a   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer; Children; Leukemia; Low risk; Predictive; Tumor lysis syndrome

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANADA; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CLINICAL FEATURE; FEMALE; GENDER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT IDENTIFICATION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SPLENOMEGALY; T LYMPHOCYTE; TUMOR LYSIS SYNDROME; UNIVARIATE ANALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 35048855741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22990     Document Type: Article

References (21)

1. Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol. 1995;12:129-134.
2. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med. 1980;68:486-491.
3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127:3-11.
4. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116: 546-554.
5. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.
6. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21:4402-4406.
7. Goldman SC. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther. 2003;3:429-433.
8. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
9. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160-165.
10. Csako G, Magrath IT, Elin RJ. Serum total and isoenzyme lactate dehydrogenase activity in American Burkitt's lymphoma patients. Am J Clin Pathol. 1982;78:712-717.
11. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993;94:133-139.
12. Kopecna L, Dolezel Z, Osvaldova Z, Starha J, Hrstkova H. The analysis of the risks for the development of tumour lysis syndrome in children. Bratisl Lek Listy. 2002;103:206-209.
13. Rajagopal S, Lipton JH, Messner HA. Corticosteroid induced tumor lysis syndrome in acute lymphoblastic leukemia. Am J Hematol. 1992;41:66-67.
14. Sparano J, Ramirez M, Wiernik PH. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer. 1990;65:1072-1073.
15. Seidemann K, Meyer U, Jansen P, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin Padiatr. 1998;210:279-284.
16. Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol. 1985;3:1590-1595.
17. Al-Kasim FA, Thornley I, Rolland M, et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol. 2002;116:483-490.
18. Brereton HD, Anderson T, Johnson RE, Schein PS. Hyperphosphatemia and hypocalcemia in Burkitt lymphoma. Complications of chemotherapy. Arch Intern Med. 1975; 135:307-309.
19. Stapleton FB, Strother DR, Roy S 3rd, Wyatt RJ, McKay CP, Murphy SB. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82:863-869.
20. Berg C, Tiselius HG. The effect of pH on the risk of calcium oxalate crystallization in urine. Eur Urol. 1986;12:59-61.
21. Albano EA, Sandler E. Oncological emergencies. In: Altman AJ, ed. Supportive Care of Children with Cancer: Current Therapy and Guidelines from the Children's Oncology Group, 3rd ed. Baltimore, Md: Johns Hopkins University Press; 2004:221-242.